So far, Compugen has shown that COM503 restores human tumor-infiltrating lymphocytes (TILs) and NK cell activity in human assays and that anti-mouse IL-18BP antibody is effective as a monotherapy in mouse breast cancer, colorectal cancer, and melanoma tumor models (Menachem et al., 2024) [92]. This evidence concerns the gene IL18BP and colorectal cancer.